These reactive oxygen species can damage cells and are found in important disease states, such as high blood pressure and aortic aneurysms. Aortic aneurysms are balloon-like swellings of the body ...

Differential aortic aneurysm formation provoked by chemogenetic oxidative stress. Journal of Clinical Investigation , 2025; 135 (9) DOI: 10.1172/JCI188743 Cite This Page : ...

Aortic stenosis is a progressive and potentially fatal condition, affecting about five per cent of 65-year-olds in the US -- with increasing prevalence in advancing age. Symptoms include chest ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...

Patency or thrombosis of the false lumen in type B acute aortic dissection has been found to predict outcomes. The prognostic implications of partial thrombosis of the false lumen have not yet ...

A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards Lifesciences’ TAVR platform is the first to be approved in this population.

Get Instant Summarized Text (Gist) The FDA has approved the SAPIEN 3 TAVR platform for patients with severe asymptomatic aortic stenosis. In a median 3.8-year follow-up, TAVR reduced the combined ...

This innovative technique provides new hope for patients with complex, life-threatening aortic aneurysms who previously had limited treatment options. Kim Baker, senior vice president of hospital ...

His father had died from an aortic aneurysm at age 63. Sternbach said it is a major breakthrough. “We’re dealing with one of vascular medicine’s most complex and dangerous conditions.

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...